History is full of great powers that hit a peak of competitive power and then stagnate and eventually decline. Few nations in that position can renew their standing.

New RAND research finds that the United States faces precisely this challenge. 🧵
bit.ly/3wpEX33

Given the importance of the Indo-Pacific to U.S. national security, research dedicated to the region remains a major priority for RAND. I look forward to working with Miyeon to expand our portfolio in ways that are meaningful—both in the U.S. and on the Korean Peninsula.

There are few historical cases of great powers that have peaked and then managed to renew their power and standing. Can the U.S. be one such case today? Or will it stagnate and decline?

New column by David Ignatius previews a RAND report out Tuesday: washingtonpost.com/opinions/2024/…

AI tools are developing quickly, and decisionmakers are grappling with how to maximize the potential benefits, minimize the short- and long-term risks, and plan for an uncertain future.

RAND research and analysis can help. 🧵 bit.ly/3UyeZ6L

'The barrier to entry for somebody who wants to carry out a biological attack is eroding.'

New Q&A with RAND CEO Jason Matheny on AI and biorisk, 'competition without catastrophe' in the U.S.-China rivalry, and much more: wired.com/story/jason-ma…

For #EarthDay , we're highlighting some recent RAND research and commentary that can help decisionmakers prepare for a changing climate. 🧵

18% of K–12 teachers reported using AI tools in their teaching, while another 15% have tried AI at least once.

New report by researchers at RAND and @crpe_edu: bit.ly/4aXYvKu

Senior political scientist Samuel Charap has been selected to serve as our inaugural Distinguished Chair in Russia and Eurasia Policy. bit.ly/43S8i2B

How have firearm death rates in the U.S. changed over time?

Our new interactive visualization allows you to explore the data, state by state. 🧵
bit.ly/3VKDGy4

Andrew helped build the RAND Gun Policy in America initiative from the ground up and is a natural choice for this new role. His experience developing unbiased, nonpartisan, fact-based resources on gun policy is exactly what we need to broaden the initiative's research agenda.

New Q&A with RAND president & CEO Jason Matheny on national security, technology policy, and U.S. competition with China: bit.ly/3PgZ6Ph

What are the potential risks associated with artificial intelligence? Might any of these be catastrophic or even existential?

Five RAND researchers with diverse perspectives weigh in: bit.ly/43fO6Ye

President Joe Biden and former President Donald Trump are both visiting America's southern border today.

What might be needed to address the crisis at the border? What would it take to speed up asylum processing? Would that help?

RAND experts discuss: bit.ly/3SZBbEO

Jason Matheny RAND bob davis “And it’s used AI and high-performance computing in modernizing its military, for example in hypersonics.”

For the full interview, follow the link below: buff.ly/48gQjDD

More than 40% of Americans know someone who has died of a drug overdose.

New study: bit.ly/4bKARCq

This week marks the second anniversary of Russia's full-scale invasion of Ukraine.

How has the war changed in the last year? And considering the uncertain future of Western aid to Ukraine, where might the conflict go from here?

New Q&A with RAND experts: bit.ly/49iFYZb

Diarrhea is the second leading cause of death for children in low- and middle-income countries, despite the fact that nearly all such deaths could be prevented with oral rehydration salts—a small package of electrolytes.

So what's stopping practitioners from prescribing them? 🧵

It may not arrive soon, but eventually there *will* be an end to the Russia-Ukraine war. What then?

New RAND research explores how the U.S. might deal with Russia following the conflict—and why it's so important to begin planning for that now. 🧵 bit.ly/4bwvN4A

It's not too late to register for our virtual event on how to reform the planning, programming, budgeting, and execution process (PPBE). Tomorrow, 3 p.m. ET. bit.ly/42uN2Pw

Prescription drug prices in the U.S. are 2.78 times those in other countries. And the gross price of insulin is more than 9 times higher.

Those are just two takeaways from a new series of RAND reports out today on this topic. Here’s an overview… 🧵 bit.ly/3SHvX1E